Sarepta Therapeutics (SRPT) Research & Development (2010 - 2026)

Sarepta Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $154.0 million for Q1 2026.

• In Q1 2026, Research & Development fell 80.09% year-over-year to $154.0 million; the TTM figure through Mar 2026 stood at $902.6 million (down 34.48% YoY), while the FY2025 annual figure was $1.5 billion, up 89.19% from the prior year.
• Research & Development was $154.0 million for Q1 2026 at Sarepta Therapeutics, down from $325.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $773.4 million in Q1 2025 to a low of $154.0 million in Q1 2026.
• Historically, Research & Development has averaged $249.1 million across 5 years, with a median of $213.8 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Research & Development surged 285.96% in 2025, then plunged 80.09% in 2026.
• A 5-year view of Research & Development shows it stood at $213.8 million in 2022, then decreased by 8.55% to $195.5 million in 2023, then rose by 2.27% to $200.0 million in 2024, then jumped by 62.71% to $325.3 million in 2025, then slumped by 52.68% to $154.0 million in 2026.
• The last three Research & Development figures came in at $154.0 million (Q1 2026), $325.3 million (Q4 2025), and $218.9 million (Q3 2025), per Business Quant data.